"If a medical technology doesn't solve a problem you’ve personally managed in the OR, why is it anchoring your retirement portfolio?" In the professional landscape of March 2026, the gap between "clinical reality" and "financial speculation" has never been wider. While surgeons manage high-stakes variables with objective data, many physician investors remain passive passengers in their own portfolios—holding "Legacy MedTech" stocks currently being disrupted by the outpatient shift and global...

A s we enter 2026, the global financial landscape is characterized by a "K-shaped" recovery. While public markets have surged to record highs, they remain sensitive to interest rate volatility and the disruptive potential of generative AI. For the mid-career surgeon, this creates a unique opportunity to rotate capital away from "fully valued" stocks and into the high-conviction world of Private Markets.   In 2026, the medical industry isn't just a place to work; it is a premier defensive...